



[Pipeline & Products](#) / [Anti-infective Products](#)

Anti-infective Products

Starpharma has developed an innovative proprietary dendrimer called SPL7013, which has a novel mechanism of action and anti-infective properties. Starpharma has developed and launched three innovative products containing SPL7013 in various international markets.

Starpharma's marketed SPL7013 product range includes a broad-spectrum nasal spray for cold/respiratory viruses, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV, and an antiviral condom.

VIRALEZE™ Nasal Spray

Starpharma's VIRALEZE™ Nasal Spray is a broad-spectrum nasal spray intended to provide a protective barrier in the nose that traps and blocks cold/respiratory viruses. The nasal spray contains SPL7013, which has been shown in clinical, nonclinical, and laboratory studies to trap and block a broad spectrum of cold/respiratory viruses, helping to prevent their adhesion, multiplication and spread.

VIRALEZE™ has been registered in more than 35 countries and commercialised in a number of markets, including the UK, Europe, and Asia. Brand name and product claims may differ by market.

VIRALEZE™ is not approved for use or supply in Australia.

VivaGel® BV

VivaGel® BV is a novel, non-antibiotic gel developed by Starpharma for the treatment of BV and the prevention of recurrent BV and its symptoms. VivaGel® BV has been registered in more than 40 countries and commercialised in a number of markets, including the UK, Europe, Southeast Asia, Australia and New Zealand. Brand name and product claims may differ by market.

VivaGel® Condom

Starpharma's VivaGel® Condom is an antiviral condom. The condom lubricant contains SPL7013, which is an antiviral agent proven, in laboratory studies only, to inactivate HIV, herpes simplex virus (HSV) and human papillomavirus (HPV), which are viruses that cause STIs. The VivaGel® Condom has been commercialised in a number of markets, including Japan. Brand name and product claims may differ by market.

Discover More



PARTNER WITH STARPHARMA



RESEARCH PUBLICATIONS



DEP® DRUG DELIVERY

Partner with us

Contact our business development team to explore partnership opportunities with Starpharma.

Business Development

T: +61 3 8532 2700

E: busdev@starpharma.com



4-6 Southampton Crescent
Abbotsford
VICTORIA 3067
AUSTRALIA
T: +61 3 8532 2700

COMPANY

[About Starpharma](#)

[Dendrimer Technology](#)

[DEP® Drug Delivery Platform](#)

[Leadership](#)

[Our Capabilities](#)

[Research Publications](#)

[ESG](#)

PARTNERSHIPS

[Partnerships](#)

[Star Navigator](#)

PIPELINE & PRODUCTS

[DEP® Pipeline](#)

[DEP® SN38](#)

[DEP® cabazitaxel](#)

[DEP® docetaxel](#)

[DEP® radiopharmaceuticals](#)

[DEP® antibody-drug conjugates](#)

[Anti-infective Products](#)

PEOPLE & CULTURE

[Our People & Culture](#)

[Careers](#)



[Disclaimer](#) [Privacy](#) [Search](#)

© Starpharma Holdings Limited 2025 | This website is intended for people seeking information on Starpharma's business.

We respectfully acknowledge the Wurundjeri Woi Wurrung People of the Kulin Nation, who are the Traditional Owners of the land on which Starpharma is based and we pay our respects to them and their country, and to Elders past and present.